What Is Zepbound?

Zepbound (tirzepatide) is a once-weekly injectable dual GIP/GLP-1 receptor agonist, FDA-approved in November 2023 for chronic weight management. It is the same molecule as Mounjaro but carries a separate FDA approval for obesity. In the SURMOUNT-1 pivotal trial, Zepbound achieved 22.5% mean body weight loss at 72 weeks — the highest efficacy ever demonstrated by an FDA-approved anti-obesity medication.

Formulation: Weekly subcutaneous injection (single-dose pen: 2.5, 5, 7.5, 10, 12.5, 15 mg)

Mechanism: GIP/GLP-1 dual receptor agonist

Manufacturer: Eli Lilly official patient site ↗

FDA Approved: 2023 — Key Trial: SURMOUNT-1 ↗ (ClinicalTrials.gov)

Who Is Zepbound For?

FDA-Approved Indication: Chronic weight management in adults with obesity or overweight with weight-related comorbidity

Adults with initial BMI ≥30 kg/m² (obesity), or BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Also FDA-approved for the treatment of obstructive sleep apnea (2024).

Eligibility criteria: BMI ≥30 kg/m², or BMI ≥27 kg/m² with ≥1 weight-related condition (hypertension, T2D, dyslipidemia, or obstructive sleep apnea)

Dosing & Titration Schedule

The standard titration protocol for Zepbound (Tirzepatide) allows your body to adjust gradually to the medication, minimizing GI side effects. Each dose is typically maintained for 4 weeks before escalation, though your prescriber may modify this based on tolerability.

Dose	Approx. Weeks	Frequency	Phase
2.5 mg	Wk 1–4	Weekly	▶ Starting dose
5.0 mg	Wk 5–8	Weekly	→ Escalation
7.5 mg	Wk 9–12	Weekly	→ Escalation
10.0 mg	Wk 13–16	Weekly	→ Escalation
12.5 mg	Wk 17–20	Weekly	→ Escalation
15.0 mg	Wk 21–24	Weekly	★ Maintenance

Data source: FDA Prescribing Information for Zepbound. Individual titration may vary based on tolerability and clinical response.

Weight Loss & Glycemic Outcomes

Clinical trial evidence (SURMOUNT-1): 22.5% mean body weight reduction at 15 mg (SURMOUNT-1, 72 weeks)

These figures are based on clinical trial populations meeting specific inclusion criteria. Real-world results may differ due to adherence, diet, activity level, and individual biology. Calculate your projected weight loss →

Side Effect Profile

The most commonly reported side effects of Zepbound are GI-related, typically most pronounced during dose escalation. They generally improve within 2–4 weeks at a stable dose.

•Nausea
•Diarrhea
•Vomiting
•Constipation
•Abdominal Pain
•Injection Site Reaction
•Fatigue

For detailed guidance on managing specific side effects, see the Tirzepatide side effects hub →

Cost Overview

Scenario	Estimated Monthly Cost
Cash pay (no insurance)	$1,000–$1,100/month
Commercial insurance	$25/month with Eli Lilly savings card for eligible commercially insured patients
Manufacturer savings program	Eli Lilly Zepbound Savings Card — eligible commercially insured patients may pay as little as $25/month. Single-dose vials available at lower list prices.

Estimated based on Q1 2026 data. Prices vary by pharmacy, region, and insurance plan. Always verify current pricing with your pharmacy or plan.

Visit Eli Lilly’s savings program ↗ | Estimate your monthly cost →

Safety & Contraindications

Zepbound carries a Boxed Warning regarding the risk of thyroid C-cell tumors (based on animal studies). The clinical relevance in humans is unknown, but the following contraindications apply:

Personal or family history of medullary thyroid carcinoma
MEN type 2 syndrome
Hypersensitivity to tirzepatide

Pregnancy: Zepbound is not recommended during pregnancy. Discontinue at least 2 months before a planned pregnancy when possible. Discuss contraception and family planning with your prescriber.

Drug interactions: Delayed gastric emptying may affect oral medication absorption. Hypoglycemia risk with insulin or sulfonylureas.

How Does Zepbound Compare to Other Options?

See all brand comparisons →

Frequently Asked Questions

How is Zepbound different from Wegovy?

Both are approved for obesity, but Zepbound (tirzepatide) is a dual GIP/GLP-1 agonist while Wegovy (semaglutide) is a GLP-1-only agonist. In SURMOUNT-1, Zepbound produced 22.5% mean weight loss vs 14.9% for Wegovy in STEP-1 — though no head-to-head trial has directly compared them.

What was the SURMOUNT-1 trial?

SURMOUNT-1 was the pivotal phase 3 trial for Zepbound (N=2,539 adults without T2D, 72 weeks). At 15 mg, participants lost a mean of 22.5% body weight (approximately 52 lb). About 57% lost ≥20% body weight — unprecedented for an approved medication.

Is Zepbound the same as Mounjaro?

Yes — same molecule (tirzepatide), same doses, same manufacturer (Eli Lilly). Mounjaro is labeled for type 2 diabetes; Zepbound is labeled for chronic weight management and obstructive sleep apnea.

What is the Zepbound titration schedule?

Start at 2.5 mg weekly for 4 weeks, then escalate every 4 weeks: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Slow titration if side effects are intolerable.

Is Zepbound covered by insurance?

Coverage is expanding but inconsistent. Many commercial plans now cover Zepbound with prior authorization. Medicare Part D typically does not cover anti-obesity medications. Eli Lilly's savings card can reduce costs significantly for commercially insured patients.

Are there Zepbound vials available at lower cost?

Yes — Eli Lilly launched single-dose Zepbound vials at reduced list prices ($399–$550/month depending on dose) for self-pay patients without insurance coverage, through the LillyDirect pharmacy. [Verify current pricing at zepbound.lilly.com]

What side effects should I expect on Zepbound?

Most common: nausea (~25–30%), diarrhea (~16–22%), vomiting (~8–13%), constipation (~7–12%), abdominal pain (~7–11%). GI effects are highest during dose escalation and typically improve with continued use at stable doses.

Zepbound: Complete Guide to Tirzepatide (2026)